First Trust Advisors LP Raises Stock Position in Integra LifeSciences Holdings Co. (NASDAQ:IART)

First Trust Advisors LP raised its position in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 319.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 186,300 shares of the life sciences company’s stock after purchasing an additional 141,907 shares during the quarter. First Trust Advisors LP’s holdings in Integra LifeSciences were worth $4,225,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the company. Quadrant Capital Group LLC lifted its holdings in Integra LifeSciences by 5,960.9% in the fourth quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company’s stock valued at $32,000 after acquiring an additional 1,371 shares during the last quarter. Sterling Capital Management LLC lifted its stake in shares of Integra LifeSciences by 821.7% in the 4th quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company’s stock valued at $49,000 after purchasing an additional 1,931 shares during the last quarter. Nisa Investment Advisors LLC grew its holdings in shares of Integra LifeSciences by 599.6% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company’s stock worth $74,000 after purchasing an additional 2,800 shares during the period. Covestor Ltd increased its position in shares of Integra LifeSciences by 61.8% during the 4th quarter. Covestor Ltd now owns 5,423 shares of the life sciences company’s stock worth $123,000 after purchasing an additional 2,071 shares during the last quarter. Finally, Empowered Funds LLC purchased a new stake in Integra LifeSciences in the 4th quarter valued at about $180,000. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Price Performance

Shares of IART opened at $16.85 on Friday. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. Integra LifeSciences Holdings Co. has a fifty-two week low of $14.45 and a fifty-two week high of $32.66. The company has a market cap of $1.30 billion, a P/E ratio of -187.20, a PEG ratio of 0.73 and a beta of 1.24. The firm’s 50 day moving average price is $19.94 and its 200 day moving average price is $22.10.

Integra LifeSciences (NASDAQ:IART) last released its earnings results on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.85 by $0.12. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The firm had revenue of $442.65 million during the quarter, compared to analyst estimates of $445.15 million. During the same period last year, the business posted $0.89 earnings per share. Integra LifeSciences’s revenue was up 11.5% compared to the same quarter last year. On average, research analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on IART. Argus upgraded shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a research report on Monday, March 31st. Truist Financial dropped their target price on shares of Integra LifeSciences from $26.00 to $19.00 and set a “hold” rating for the company in a report on Friday, April 11th. Three research analysts have rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $22.71.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.